RA Capital Management is a Boston-based investment firm focused on healthcare, life sciences, and planetary health. The firm pursues evidence-based investing across public and private markets and provides hands-on support to portfolio companies, including through its Raven healthcare incubator. It relies on deep research via its TechAtlas knowledge engine to identify opportunities and guide value creation from early-stage ideas to commercialization. Since its inception, the firm has deployed capital across multiple rounds and has built a portfolio of hundreds of companies, backed by an ongoing effort to advance drugs, medical devices, diagnostics, and biotech tools. RA Capital manages substantial assets and seeks to invest across stages—from seed to growth—often taking leading roles or co-investing and participating in governance to support management teams. The firm emphasizes impact in healthcare and planetary health, aiming to translate bold ideas into durable improvements in patient care and public health.

MassVentures is a Massachusetts-based venture capital firm with a long history of supporting early-stage startups in the state's innovation economy. Established in 1978 to advance entrepreneurship, it provides seed and early-stage funding, mentorship, and strategic guidance to help founders move from concept to commercialization. The firm focuses on deep-tech sectors including quantum computing, clean energy, artificial intelligence, and biotech, and has funded more than 190 companies with over $4 billion in follow-on capital raised. MassVentures seeks opportunities beyond traditional hubs and prioritizes diverse founding teams, with 82% of investments in diverse founders in 2025. Its programs—MV Capital for funding, MV Accelerate for commercialization support, and MV Spinouts for academic spinout partnerships—offer tailored advice, industry connections, and practical resources to accelerate growth.

Atlas Venture is a Cambridge, Massachusetts-based venture capital firm that specializes in early-stage investments in biotechnology and life sciences, with additional focus on technology companies. It partners with life science entrepreneurs to translate scientific discoveries into medicines and related diagnostics, often leading seed or Series A rounds and providing strategic guidance and board involvement. Founded in 1980, Atlas Venture has organized multiple funds and operates with dedicated Life Sciences and Technology teams to manage portfolio companies across the United States and Europe. Its portfolio emphasizes biopharmaceuticals, therapeutics, and medical technologies, along with software and data-driven technologies that support life science commercialization.

Morningside Group is a Boston-area venture capital firm founded in 1986 as a family office for the Chan family. It makes long-term investments in companies applying novel science and technology, with expertise in life sciences, digital health, AI, materials, and technology, and a commitment to ethical business practices. The firm supports education, research, and healthcare through charitable initiatives with partners including Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and MIT Morningside Academy for Design.

Alumni Ventures is a venture capital firm that broadens access to venture and private market investments for accredited investors, including alumni networks, by enabling co-investment alongside leading VC firms. It offers investment funds, investing clubs, portfolio opportunities, and educational resources through its AV Academy, and provides support to startup founders. The firm emphasizes transparency with access to due diligence materials and live discussions, and seeks to build a diversified portfolio through collaborative investing. Headquartered in Manchester, New Hampshire, it operates with offices in New York, Boston, Menlo Park, Chicago, London and Tokyo to reach a broad investor base.

General Catalyst is a venture capital firm headquartered in Cambridge, Massachusetts, with a global presence. It backs companies across seed to growth stages, providing capital and strategic guidance to help startups scale. The firm focuses on technology-enabled sectors, including healthcare, fintech, consumer technology, enterprise software, and AI-driven ventures, supporting portfolio companies pursuing transformative innovations. General Catalyst emphasizes mentorship and hands-on support to accelerate ideas and growth, aiming to create favorable conditions for value creation. It manages multiple venture funds and oversees a broad, diverse portfolio, reflecting a commitment to advancing applied AI and other technology-enabled opportunities worldwide.

OrbiMed is a global healthcare investment firm, founded in 1989, that invests across the healthcare sector including biopharmaceuticals, medical devices, diagnostics, digital health, and healthcare services. It manages private equity, venture capital, and public equity investments, and provides financing solutions such as private debt and royalty monetization to support the development of new therapies and medical technologies. With a broad, globally distributed team, OrbiMed operates across multiple markets and provides strategic resources to companies from early-stage to growth, aiming to advance scientific innovation and improve patient outcomes.

Flagship Pioneering is a Cambridge, Massachusetts-based venture creation firm that conceives, creates, resources, and grows first-in-category ventures to transform human health and sustainability. It combines scientific discovery with entrepreneurial capital to envision and realize new companies in biology, engineering, medicine, energy, and related fields, guided by an evolutionary methodology. The firm builds companies from innovative ideas and fosters strategic collaborations, supporting a diverse portfolio that includes Moderna, Tessera Therapeutics, and Generate Biomedicines, as well as partnerships with large industry players such as AWS, Pfizer, and GSK to accelerate drug discovery and development. Founded in 2000, Flagship Pioneering operates as a leading venture firm and investment adviser, emphasizing long-term value creation through disciplined science-driven entrepreneurship.

ARCH Venture Partners is a Chicago-based venture capital firm with offices in Seattle that concentrates on life sciences and science-driven startups. Founded in 1986, it partners with scientists and entrepreneurs to bring innovations to market by providing capital, strategic guidance, and access to networks across the company’s lifecycle. The firm emphasizes translational work from academic research and national laboratories, and has raised more than $3 billion across multiple funds and invested in more than 150 companies, highlighting a hands-on approach to catalyzing discovery and execution in the life sciences sector.

Mission BioCapital is a life science venture capital firm that backs early-stage biotechnology and health science startups. Founded in 2009 and based in Cambridge, Massachusetts, with an office in San Francisco, the firm leverages a long-standing leadership team and a broad network to provide hands-on mentorship, strategic guidance, and resources such as shared laboratory space to portfolio companies. It emphasizes collaboration, innovation, and support for founders from diverse backgrounds, helping startups advance through research, development, and early commercial stages in the life sciences sector.

Invus is a global investment firm with more than four decades of experience partnering with entrepreneurs to transform industries. Since 1985 it has built a patient, long-term capital base and aligns incentives with management to support lasting value creation. The firm manages substantial evergreen capital and operates offices in New York, London, Paris, and Hong Kong, enabling private equity investments, co-investments, and selective opportunities worldwide. It pursues a flexible, non-formulaic approach and focuses on minority and selective control investments across sectors including consumer products and services, technology, life sciences, software, agtech, industrials, education, and medical devices. Invus emphasizes hands-on partnership, strategic guidance, and durable relationships, partnering with market-leading management teams to back growth through private transactions and syndicated financings, with a long-term orientation and capital structures designed to sustain portfolio companies as they scale.

Founder Collective is a seed-stage venture capital firm focused on technology startups. Founded in 2009 by entrepreneurs who have built and exited technology companies, it emphasizes founder-aligned partnerships and capital efficiency, aiming to minimize dilution while supporting portfolio companies from idea to IPO. The firm takes a technology-centric, stage-agnostic approach within seed and early stages and makes investments across the United States and worldwide. Headquartered in Cambridge, Massachusetts, with an office in New York City, Founder Collective leverages the experience of its founders to provide hands-on guidance to portfolio companies. It is built by a collection of successful entrepreneurs and concentrates on backing ambitious teams with potential to reshape industries, prioritizing authenticity, long-term value creation, and close collaboration with founders.

New Enterprise Associates is a global venture capital firm founded in 1977 and headquartered in Menlo Park, California, with additional offices in the United States, India and China. The firm invests in technology and healthcare companies across all stages, from seed through IPO, with a broad sector focus that includes software, consumer technology, medical devices, life sciences, healthcare information technology, energy technology and related areas. NEA partners with founders to provide capital, domain expertise and strategic support for product development and market expansion, helping navigate changing economic environments. The firm maintains a track record of backing a large number of portfolio companies, with more than 210 IPOs and over 360 acquisitions.

Third Rock Ventures is a venture capital firm founded in 2007 and headquartered in Boston, Massachusetts, with additional offices in San Francisco. It focuses on life sciences and healthcare, including biotechnology, medicine, drugs, devices, diagnostics, therapeutics, and related information technology. The firm invests in early-stage and startup companies with high growth potential and transformative potential in healthcare. It typically leads rounds and pursues active involvement in portfolio companies, including strategic collaborations and hands-on management where appropriate, to help build companies from concept to market. Its approach emphasizes developing patient-centered solutions and advancing therapies and technologies across multiple therapeutic areas, including oncology, autoimmune diseases, and gene therapy. The firm generally concentrates its investments in U.S.-based life sciences companies and seeks to partner with entrepreneurs to accelerate development of medicines, diagnostics, and medical technologies.

Accomplice is a seed-led venture capital firm based in Cambridge, Massachusetts, that backs early-stage technology startups. The firm focuses on cybersecurity, esports, data analytics, SMB-class software, emerging hardware platforms, and marketplaces, and supports founders through a community-driven model that leverages platforms and networks to fund and accelerate ventures. Originating as Atlas Venture, the technology group was renamed Accomplice in 2014 as part of a strategic split between technology and life sciences franchises. Accomplice maintains a strong presence in the New England startup ecosystem and invests across the United States, Canada, and Europe.

SOSV is a global venture capital firm that backs deep-tech startups through multi-stage investments and hands-on programs. It focuses on pre-seed and early-stage funding across healthcare, AI, robotics, hardware, and cross-border software, and supports founders with intensive mentorship, prototyping facilities, and access to a broad investor network to accelerate product development and fundraising toward Series B. The firm operates dedicated deep-tech facilities, including IndieBio, renamed SOSV SF & NY, and HAX in Newark, providing laboratory and engineering space, and maintains a global footprint with offices in New York, Newark, San Francisco, Silicon Valley, Pune, Shenzhen, and Tokyo. SOSV emphasizes long-term founder relationships and program-driven growth, backed by a substantial portfolio and capital deployed across multiple regions.

Casdin Capital is a New York-based investment firm founded in 2012 by Eli Casdin that focuses on the life sciences and healthcare sectors. It pursues investments across oncology, digital health, agtech, and broader biotechnology and medical areas, including early- to late-stage private opportunities. The firm employs a fundamental, research-driven approach and leverages deep industry expertise to identify ventures with potential to advance science and patient care. It acts as a partner to companies at the intersection of biology and medicine, supporting science-based innovation through capital allocation and guidance.

Hyperplane Venture Capital is an early-stage venture capital firm based in Boston that invests in technology startups, with a focus on machine intelligence, data, and related technologies such as artificial intelligence, cloud computing, distributed systems, automation, robotics, and sensor-enabled platforms.

Spark Capital is a venture capital firm founded in 2005 and based in San Francisco, Boston, and New York City. It invests in startups across stages and sectors, with a focus on consumer, software, fintech, media, and related areas, and prioritizes supporting ambitious founders and distinctive products. The firm engages with early-stage and growth opportunities, aiming to collaborate with management teams to help scale while taking a thoughtful, risk-tolerant approach rather than adhering to a single playbook. Spark Capital has backed notable companies such as Twitter, Discord, Anthropic, Cruise, Niantic, Oculus, Warby Parker, and Tumblr, reflecting its history of partnering with category-defining teams and its broad geographic footprint in the United States.

406 Ventures is a Boston-based venture capital firm founded in 2005 that focuses on early-stage and de novo investments in information technology, cybersecurity and infrastructure, data and cloud technologies, and technology-enabled business services. It backs enterprise IT, software, AI, big data, digital health, fintech and related sectors, often serving as lead or first institutional investor and reserving capital for follow-on rounds. The firm leverages a veteran team with deep industry experience to provide strategic guidance, networks and operational support to help portfolio companies scale. Headquartered in Boston, it targets opportunities across the Northeast United States, partnering with entrepreneurs to translate technology into scalable, market-ready businesses.

Beacon Angels is a Boston-based angel investment group founded in 2006 that funds early-stage, high-growth companies in New England. The group typically invests in the range of tens of thousands to a few hundred thousand dollars per company and conducts regular screening of opportunities, with monthly meetings for accredited members and scheduled reviews of new ventures, aiming to grow portfolio value through shared capital and strategic relationships.

Deerfield Management is a New York-based healthcare investment firm that advances human health through investment, research, and philanthropy. It manages investment strategies across public and private markets in biotechnology, pharmaceuticals, diagnostics, medical devices, digital health, and healthcare services, and supports early-stage innovation through strategic partnerships and dedicated facilities that foster scientific research and drug discovery. The firm operates a philanthropic foundation focused on education, healthcare access, and initiatives aimed at improving health outcomes.

TCG Crossover is a science-driven healthcare investment firm dedicated to advancing disruptive medicines and supporting companies that can improve patients' lives. It invests in both private and public companies led by entrepreneurs developing better treatment options, with teams in Palo Alto and New York City. The firm leverages scientific expertise to identify and back breakthrough pharmaceutical therapies and health technology opportunities, aiming to accelerate innovation in the pharmaceutical sector and to help management teams translate discovery into patient benefit.

Boston Seed Capital is a Boston-area venture capital firm focused on seed- and early-stage investments in internet-enabled and technology-driven companies. It targets consumer brands, B2B software-as-a-service, marketplaces, and supporting services, as well as information technology, cybersecurity, e-commerce, big data, AI and machine learning, and related sectors. Founded in 2010 and headquartered in the Boston area with an office in Wellesley Hills, the firm backs founders from pre-seed to growth stages and supports ideas that aim to drive meaningful change.

Safar Partners is a Cambridge, Massachusetts based venture capital firm founded in 2018 that focuses on seed- to growth-stage technology startups in the United States, leveraging connections to leading universities such as MIT, Harvard, and the University of Rochester to source and support early-stage companies. It invests across sectors including cleantech, advanced materials, artificial intelligence and IT and robotics, and life sciences and medical devices, with a flexible investment approach designed to help companies grow from inception to global scale, and it emphasizes environmental, social, and governance considerations in its investment process to pursue sustainable innovation and strong financial returns.

Northpond Ventures is a science-driven venture capital firm based in Bethesda, Maryland, with offices in San Francisco and Cambridge. Founded in 2018, it provides growth capital to companies operating in life sciences, diagnostics, digital health, health tech, therapeutics, medical devices and related technology-enabled sectors, supporting ventures that advance scientific innovation and improve healthcare outcomes.

Launchpad Venture Group is a Boston, Massachusetts-based angel investment group that supports early-stage technology and life science companies in the United States, with a strong focus on New England. It provides capital and mentorship, leveraging a network of individual investors to back startups across software, information technology, web and mobile, digital media and social platforms, medical devices and diagnostics, healthcare IT, networking and telecom, clean-tech, and renewable energy sectors. Since 2001, it has invested more than $125 million in over 150 startups. The firm seeks new investment opportunities and welcomes participants interested in engaging with the regional startup ecosystem.

Pillar VC is a Boston-based venture capital firm focused on early-stage, technically driven startups. It collaborates with founders from inception, using a lab-to-launch playbook to translate research into market-leading companies. The firm emphasizes university-rooted origin stories and backs ventures across healthcare, AI, biotechnology, computing, and enterprise intelligence. Its portfolio includes companies such as Abridge, Latent Labs, and Neural Magic, illustrating a track record of supporting research-driven startups with potential for significant value creation.

MPM BioImpact is a biotechnology-focused investment firm based in Boston that builds and funds companies transforming patient outcomes through drug development. With more than 30 years of experience, it invests in both private and public companies across various stages of the drug development process, spanning early to late-stage programs and across the biotechnology, healthcare, and life sciences sectors in the United States. The firm supports portfolio companies with leadership, expertise, and strategic guidance, collaborating with experienced individuals and academic institutions. Its portfolio includes Aktis Oncology, Orna Therapeutics, Reunion Neuroscience, and argenx, among others, reflecting a focus on innovative therapies that aim to translate scientific breakthroughs into life-saving medicines.

CRV, originally Charles River Ventures, is an early-stage venture capital firm founded in 1970 with offices in Palo Alto, Cambridge and Menlo Park. It focuses on seed to Series B investments in technology, consumer products and services, and healthcare across North America. CRV takes a value-added, hands-on approach, partnering with portfolio founders to navigate development from inception through growth and beyond. As one of the industry’s longest-running firms, CRV combines capital with strategic guidance to help entrepreneurs turn ideas into category-leading companies.

Prelude Ventures is a venture capital firm based in San Francisco that invests in early-stage startups focused on mitigating climate change. Since its founding in 2013, it supports companies across sectors including the built environment, carbon management, compute, energy, food and agriculture, manufacturing and industrials, and mobility, with the aim of backing category-defining businesses. The firm emphasizes practical climate action and provides capital and guidance to help portfolio companies scale their solutions to reduce environmental impact.

Khosla Ventures is a venture capital firm based in Menlo Park, California, that funds and supports technology companies across stages and sectors, including artificial intelligence, healthcare, climate tech, digital health, and consumer technology. It provides capital and strategic guidance to help startups develop innovative products, scale operations, and build enduring businesses, with an emphasis on science-driven, high-impact ventures and unconventional ideas. Founded by Vinod Khosla, the firm seeks to back companies addressing large, underserved markets and to contribute hands-on support beyond funding.

Tiger Global Management is a globally focused, research-driven investment firm founded in 2001 by Charles (Chase) Coleman. It makes long-term investments in both public and private markets across the United States and other regions, with a strong emphasis on technology, internet, consumer, and financial services sectors. The firm employs growth-oriented strategies in public equities and supports early to late-stage private companies through private investments, aiming to back high-quality, innovative businesses across their lifecycles. As an SEC-registered investment advisor, Tiger Global provides disciplined capital allocation and seeks partnerships with portfolio companies over the long term, leveraging global reach and industry expertise. Headquarters are in New York.

E14 Fund is a Cambridge, Massachusetts-based venture capital firm founded in 2013 that concentrates on seed-stage investments in deep technology companies, including startups originating from MIT. The firm aims to translate laboratory ideas into real-world products by backing technologies with broad applications across AI, robotics, biotech, smart cities, and manufacturing. It leverages a network of advisors and the broader founder community to help portfolio companies scale, raise subsequent rounds, and connect with talent and resources. The firm emphasizes diversity and inclusion, with founders from diverse backgrounds contributing to its portfolio. Investments typically range from pre-seed to Series A, and the firm supports its portfolio teams through a collaborative, community-oriented approach designed to accelerate growth and impact.

G20 Ventures is a venture capital firm based in the Cambridge/Boston area of Massachusetts that invests in early‑stage enterprise software and infrastructure companies on the East Coast. Established in 2013, it targets Series A rounds with typical checks of 2 to 5 million and reserves capital for earlier or follow‑on investments to stay with portfolio companies. The firm prioritizes technology risk over market risk and seeks teams with a technologist and a business leader who deeply understands the buyer and go‑to‑market. A product in the market with some customer validation is preferred. G20 provides hands‑on support and builds a community of founders, operators, and investors to aid growth through strategic capital deployment, aiming for long‑term value creation and efficient capital utilization with minimal dilution as companies scale.

EcoR1 Capital is a San Francisco-based venture capital firm focused on supporting early-stage biotechnology companies developing innovative therapies. The firm seeks to back entrepreneurs driving therapeutic innovation and positions itself as a strategic partner to navigate drug discovery and development, leveraging scientific curiosity and a deep biotech background to identify valuable opportunities in biotech and help advance new medicines.

Sequoia Capital is a venture capital firm founded in 1972 and based in Menlo Park, California. It provides capital alongside strategic guidance to a limited number of technology-focused companies across seed, early, and growth stages, supporting product development, company building, and market expansion. The firm emphasizes long-term partnerships with founders and engages across a global footprint, with activity in the United States and internationally in regions such as China, India, and Israel.

Gutbrain Ventures is a Boston-based independent venture firm that primarily invests in enterprise software companies. The firm is led by Bob Davoli, an experienced investor and software operator known for a direct, supportive approach and strategic guidance throughout a company's lifecycle. Gutbrain Ventures emphasizes long-term growth and strategic partnerships, aiming to create value for founders and stakeholders. It maintains a portfolio across sectors and has a history of successful exits and companies with IPO potential, while supporting diverse founders, including women entrepreneurs.

Venrock is a venture capital firm founded in 1969 as the venture capital arm of the Rockefeller family. It concentrates on seed and early-stage investments across technology and healthcare, with interest in AI, biotechnology, fintech, data analytics, cybersecurity, cloud and software, and related life sciences sectors. The firm supports startups in the United States, with a strong presence in Silicon Valley and New York, and has a history of backing notable technology and healthcare companies such as Apple Computer, Intel, Illumina, Athenahealth, Gilead Sciences, DoubleClick, Endeca, Nest, SlideShare and Tudou. Venrock pursues exits through acquisitions and IPOs and partners with entrepreneurs to build enduring companies.

CVP Management is a venture capital firm focused on early‑stage technology investments, including seed and early Series A rounds. It concentrates on information technology infrastructure with emphasis on software applications, internet, digital media, digital marketing, vertical SaaS, cloud, embedded software, mobile, and financial services technologies. The firm typically invests from $0.1 million to $1 million, and for seed and Series A rounds from $1 million to $3.5 million, in companies with an enterprise value around $5 million. It prefers to hold a seat on the portfolio company board and to invest in preferred stock. The firm funds companies located in the Northeast corridor, especially Boston, New York, and Toronto, and began operation on June 1, 1998, with headquarters in Cambridge, Massachusetts, and an additional office in Boston.

Samsara BioCapital is a Palo Alto-based investment firm founded in 2016 that specializes in biotechnology and healthcare. The firm seeks to invest in biotechnology companies across the United States, with a focus on developing transformative therapeutics. It emphasizes collaboration among scientists, physicians, drug developers, and business leaders to advance innovative medicines. As a registered investment adviser and principal investment firm, Samsara BioCapital provides investment advisory services and pursues opportunities to support entrepreneurs in turning ideas into therapies. The company aims to foster biotech innovation by partnering with ambitious teams and supporting approaches that bring meaningful new treatments to patients.

Boxer Capital is a biotechnology investment firm and the corporate venture capital arm of Tavistock Group, based in San Diego and founded in 2005. It invests in public and private biotechnology and life sciences companies across the drug development lifecycle, with an emphasis on precision medicine. The firm employs a research-driven, bottom-up due diligence process grounded in scientific, clinical, and regulatory perspectives to identify opportunities that aim to advance patient care and drive medical innovation.

Right Side Capital Management is a San Francisco-based venture capital firm that backs early-stage, capital-efficient technology companies in the United States and Canada. It employs a quantitative, data-driven approach to identify opportunities, enabling fast, transparent funding decisions. The firm typically writes small checks in the range of 50,000 to 500,000 and provides founders with mentorship, operational guidance, and access to later-stage investors. Focusing on startups outside major hubs, it emphasizes revenue-generating models with scalable potential and aims to build a diversified portfolio while delivering practical post-investment support.

Sigma Partners is a venture capital firm founded in 1984 that focuses on early-stage investments. It is based in Boston, Massachusetts, with additional offices in Menlo Park and San Ramon, California. The firm has backed numerous early-stage companies across sectors such as semiconductors, mobile computing, electronics, infrastructure, internet, and software, and has managed over $2 billion in capital. The organization has since split into two independent firms: Jackson Square Ventures (formerly Sigma West) and Sigma Prime Ventures.

Boston Harbor Angels is an angel investment group based in Boston, Massachusetts, formed in 2004. The group comprises experienced business leaders who invest their personal capital in high-growth, early-stage companies across sectors such as information technology, life sciences, healthcare, fintech, consumer products, and cleantech. They typically support rounds of about 250,000 to 1.5 million and prefer companies close to commercialization with a defensible competitive advantage, aiming for profitability with less than 5 million of equity investment and a potential tenfold return within five years. Investments are made on an individual basis, though members collaborate in due diligence and often lead in life sciences; the group also syndicates with other angel groups or venture funds. The organization is governed by an executive committee and manages day-to-day operations through a managing director. Beyond capital, Boston Harbor Angels offer mentorship, networking, and expert guidance to entrepreneurs.

Omega Funds is a Boston-based venture capital firm focused on investing in life sciences and healthcare companies across North America and Western Europe. Founded in 2004, the firm targets opportunities in oncology, immunology, rare diseases, precision medicine, digital health, cybersecurity, and software-as-a-service, providing capital and strategic support to entrepreneurs and founders. With emphasis on early-stage and growth-oriented opportunities, Omega Funds leverages an experienced team, a broad industry network, and a track record of helping portfolio companies advance products to patients and achieve strategic exits through public listings or acquisitions. The firm positions itself as a value-added investor, aligning scientific advancement with business development to drive meaningful clinical and commercial outcomes in the life sciences space. It operates as a registered investment adviser with international exposure across North America and Western Europe.

Longwood Fund is a Boston-based life science venture investment firm focused on identifying and supporting innovative technologies and the teams developing them to advance patient care. It funds and guides early-stage science through clinical development and commercialization, concentrating on healthcare, pharmaceutical, and biotechnology sectors. The firm leverages a broad network of industry experts to advise and accelerate the growth of its portfolio companies from discovery to market. Since its founding in 2010, Longwood has demonstrated a track record of translating scientific breakthroughs into tangible treatments, with several portfolio companies bringing products to market and multiple therapies advancing in late-stage development. The organization continues to seek opportunities in promising life science ventures and provides strategic support to teams throughout the development journey.

Refactor Capital is a California-based venture capital firm that specializes in seed-stage hard-tech investments. Based in Burlingame, it is led by Zal Bilimoria as a sole founder and concentrates on early-stage companies across the United States in areas such as bio, energy, earth systems, aerospace, manufacturing, and critical materials. The firm pursues real-world applications of technology and acts as a proactive partner to founders, typically making checks in the range of $1-2 million to support product development and market entry.

5AM Ventures is a San Francisco-based venture capital firm founded in 2002 by John Diekman and Andrew Schwab. The firm specializes in seed- and early-stage investments in life sciences, healthcare, and related technologies, with a portfolio spanning biopharmaceuticals, medical technology, and research instruments. It maintains a presence in Boston in addition to its San Francisco headquarters and pursues two primary strategies: venture capital investments in early-stage private companies typically seeking Series A financing, and public equity investments in select biotech and life science firms. 5AM Ventures emphasizes hands-on support, partnering with academics and entrepreneurs to build proof-of-concept data and to advance clinical and commercial milestones. Through its focus on healthcare and life sciences, the firm aims to advance next-generation therapies, diagnostics, and tools that address unmet medical needs.

Dementia Discovery Fund is a venture capital organization focused on dementia therapeutics and enabling technologies. Managed by SV Health Investors, it operates as a family of specialized funds that invests exclusively in companies developing novel dementia treatments or the tools that advance them. With offices in London and Boston, it leverages a global network of venture partners, scientists, and strategic collaborators to identify opportunities, form new biotech ventures, and support early-stage development. The organization pursues a dual mandate of delivering measurable patient impact and generating financial returns, supported by a diverse set of investors including pharmaceutical companies, healthcare organizations, and philanthropic partners, all aimed at accelerating progress toward effective therapies for Alzheimer’s disease and related conditions.